(Hyperlinks to references in text)
[1] Parkin DM, Bray F, Ferlay J and Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
[2] Gourin CG, Podolsky RH. Racial disparities in patients with head and neck squamous cell carcinoma. Laryngoscope. 2006;116:1093-1106.
[3] Argiris A, Karamouzis MV, Raben D and Ferris RL. Head and neck cancer. Lancet. 2008;371:1695-1709.
[4] Seiwert TY, Salama JK and Vokes EE. The chemoradiation paradigm in head and neck cancer. Nat Clin Pract Oncol. 2007;4:156-171.
[5] Salama JK, Seiwert TY and Vokes EE. Chemoradiotherapy for locally advanced head and neck cancer. J Clin Oncol. 2007;25:4118-4126.
[6] Browman GP, Hodson DI, Mackenzie RJ, Bestic N and Zuraw L. Choosing a concomitant chemotherapy and radiotherapy regimen for squamous cell head and neck cancer: A systematic review of the published literature with subgroup analysis. Head Neck. 2001;23:579-589.
[7] Pignon JP, le Maitre A and Bourhis J. Meta-Analyses of Chemotherapy in Head and Neck Cancer (MACH-NC): an update. Int J Radiat Oncol Biol Phys. 2007;69:S112-S114.
[8] Bourhis J, le Maitre A, Baujat B, Audry H and Pignon JP. Individual patients’ data meta-analyses in head and neck cancer. Curr Opin Oncol. 2007;19:188-194.
[9] Budach W, Hehr T, Budach V, Belka C and Dietz K. A meta-analysis of hyperfractionated and accelerated radiotherapy and combined chemotherapy and radiotherapy regimens in unresected locally advanced squamous cell carcinoma of the head and neck. BMC Cancer. 2006;6:28.
[10] Doweck I, Denys D and Robbins KT. Tumor volume predicts outcome for advanced head and neck cancer treated with targeted chemoradiotherapy. Laryngoscope. 2002;112:1742-1749.
[11] Robbins KT, Doweck I, Samant S, Vieira F and Kumar P. Factors predictive of local disease control after intra-arterial concomitant chemoradiation (RADPLAT). Laryngoscope. 2004;114:411-417.
[12] Mendenhall WM, Morris CG, Amdur RJ, Hinerman RW and Mancuso AA. Parameters that predict local control after definitive radiotherapy for squamous cell carcinoma of the head and neck. Head Neck. 2003;25:535-542.
[13] Prosnitz RG, Yao B, Farrell CL, Clough R and Brizel DM. Pretreatment anemia is correlated with the reduced effectiveness of radiation and concurrent chemotherapy in advanced head and neck cancer. Int J Radiat Oncol Biol Phys. 2005;61:1087-1095.
[14] Chufal KS, Rastogi M, Srivastava M, Pant MC, Bhatt ML and Srivastava K. Analysis of prognostic variables among patients with locally advanced head and neck cancer treated with late chemo-intensification protocol: impact of nodal density and total tumor volume. Jpn J Clin Oncol. 2006;36:537-546.
[15] Rudat V, Dietz A, Schramm O et al. Prognostic impact of total tumor volume and hemoglobin concentration on the outcome of patients with advanced head and neck cancer after concomitant boost radiochemotherapy. Radiother Oncol. 1999;53:119-125.
[16] Sanguineti G, Corvo R, Sormani MP et al. Chemotherapy alternated with radiotherapy in the treatment of advanced head and neck carcinoma: predictive factors of outcome. Int J Radiat Oncol Biol Phys. 1999;44:139-147.
[17] Doweck I, Robbins KT and Vieira F. Analysis of risk factors predictive of distant failure after targeted chemoradiation for advanced head and neck cancer. Arch Otolaryngol Head Neck Surg. 2001;127:1315-1318.
[18] Denys D, Kumar P, Wong FS, Newman LA and Robbins KT. The predictive value of tumor regression rates during chemoradiation therapy in patients with advanced head and neck squamous cell carcinoma. Am J Surg. 1997;174:561-564.
[19] Gasparini G, Bevilacqua P, Bonoldi E et al. Predictive and prognostic markers in a series of patients with head and neck squamous cell invasive carcinoma treated with concurrent chemoradiation therapy. Clin Cancer Res. 1995;1:1375-1383.
[20] Knegjens JL, Pameijer FA, Balm AJM, Hauptmann M, Hoebers FJ and Rasch CRN. Tumor Volume as Outcome Predictor in Chemoradiation for Advanced Head and Neck Cancer. Int J Radiat Oncol Biol Phys. 2007;69:S410-S411.
[21] Chen SW, Yang SN, Liang JA, Lin FJ and Tsai MH. Prognostic impact of tumor volume in patients with stage III-IVA hypopharyngeal cancer without bulky lymph nodes treated with definitive concurrent chemoradiotherapy. Head Neck. 2009.
[22] Klussmann JP, Mooren JJ, Lehnen M et al. Genetic signatures of HPV-related and unrelated oropharyngeal carcinoma and their prognostic implications. Clin Cancer Res. 2009;15:1779-1786.
[23] Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J and Overgaard J. Effect of HPV-associated p16INK4A expression on response to radiotherapy and survival in squamous cell carcinoma of the head and neck. J Clin Oncol. 2009;27:1992-1998.
[24] Fakhry C, Westra WH, Li S et al. Improved survival of patients with human papillomavirus-positive head and neck squamous cell carcinoma in a prospective clinical trial. J Natl Cancer Inst. 2008;100:261-269.
[25] Ragin CC, Taioli E. Survival of squamous cell carcinoma of the head and neck in relation to human papillomavirus infection: review and meta-analysis. Int J Cancer. 2007;121:1813-1820.
[26] Weinberger PM, Yu Z, Haffty BG et al. Molecular classification identifies a subset of human papillomavirus–associated oropharyngeal cancers with favorable prognosis. J Clin Oncol. 2006;24:736-747.
[27] Dumur CI, Ladd AC, Wright HV et al. Genes involved in radiation therapy response in head and neck cancers. Laryngoscope. 2009;119:91-101.
[28] Ginos MA, Page GP, Michalowicz BS et al. Identification of a gene expression signature associated with recurrent disease in squamous cell carcinoma of the head and neck. Cancer Res. 2004;64:55-63.
[29] Ganly I, Talbot S, Carlson D et al. Identification of angiogenesis/metastases genes predicting chemoradiotherapy response in patients with laryngopharyngeal carcinoma. J Clin Oncol. 2007;25:1369-1376.
[30] Chung CH, Parker JS, Karaca G et al. Molecular classification of head and neck squamous cell carcinomas using patterns of gene expression. Cancer Cell. 2004;5:489-500.
[31] Chung CH, Parker JS, Ely K et al. Gene expression profiles identify epithelial-to-mesenchymal transition and activation of nuclear factor-kappaB signaling as characteristics of a high-risk head and neck squamous cell carcinoma. Cancer Res. 2006;66:8210-8218.
[32] Pramana J, Van den Brekel MW, van Velthuysen ML et al. Gene expression profiling to predict outcome after chemoradiation in head and neck cancer. Int J Radiat Oncol Biol Phys. 2007;69:1544-1552.
[33] Slebos RJ, Yi Y, Ely K et al. Gene expression differences associated with human papillomavirus status in head and neck squamous cell carcinoma. Clin Cancer Res. 2006;12:701-709.
[34] www.oncoline.nl, accessed 2009.
[35] Rasch CR, Balm AJ, Kroger R, et al. Intra-arterial versus intravenous chemoradiation for advanced head and neck cancer: results of a Phase III Trial. Cancer. 2009. In press.
[36] van den Broek GB, Wildeman M, Rasch CR et al. Molecular markers predict outcome in squamous cell carcinoma of the head and neck after concomitant cisplatin-based chemoradiation. Int J Cancer. 2009;124:2643-2650.
[37] Lassen P, Eriksen JG, Hamilton-Dutoit S, Tramm T, Alsner J and Overgaard J. HPV-associated p16-expression and response to hypoxic modification of radiotherapy in head and neck cancer. Radiother Oncol. 2009.